Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CUBT is not trying to save the world from COVID, just trying to provide a solution to an underserved market, like those with compromised immune systems (those with kidney issues), who are not getting any protection from the current vaccines.
CUBT wonder what the rhyme of the day will be when the company is longer on the pinks. No more stinky pinky. LOL.
The stock is returning to earth on low volume which is what happens on nearly all OTC stocks. The move will come. Myth, eh? There is manipulation on this symbol as there is with every symbol. Why do you think the bears who have no vested interest here post at 5:30am every day? It is called market manipulation. Time will prove this out.
Personally just think they (market makers/manipulators) trying to wear people down. Get them impatient. Frustrated, so they dump their shares. Right before letting it run. I understand how you feel. But when the stock is at .08 one minute then taken down to mid .06’s it is not someone dumping shares. It is market makers selling to keep the price low. All this is happening on low volume. This happens every day. This happened to me. Had a stock I got frustrated with sold at .07 a couple weeks before it ran, to 3.00. That one hurt since I had 2M shares. Good luck.
No one has mentioned this but interesting that the pathway forward for the Covid vaccine is Operation Warp Speed, which continues under the Biden admin and will be rebranded under a new name (assuming here they want their own brand now versus what Trump created). I believe this is the first time the company has listed this in any material.
With today’s news about the new variant that sent the market tumbling, Covid is not going anywhere. And this new variant is much more contagious, and could potentially put those with compromised immune systems, like those with kidney disease, at greater risk. The current vaccines have not proven to be effective among this population.
Just a reminder of Dr. Catherine Sohn’s background…
“Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee.”
I doubt if she is sitting around doing nothing as some have claimed. Connect the dots. Think she knows a thing or two about brining vaccines to market.
No product? LOL. Someone obviously is not familiar with how biotech companies work.
Here is their current pipeline…
https://curativebiotech.com/pipeline
Great points. Totally agree. They have big plans imo. In football terms they are working on their X’s and O’s. It is football season so why not. Thanks for the insights.
Yep. The audit is complete. Pieces coming together. News drop coming imo that will show the progress they are making.
If you are going to print past prices be accurate. Guesstimates just feed one’s narrative
It was not under a penny one year ago. Check your facts.
Agreed. Buy when there is in blood in the water and emotions running high to scare people into selling. I’ve got my orders in today.
This is part of the diabolical responses I have read here. Say what one might about Barry, Richard Garr is one of the most stand up CEO’s you will meet. Check his history. And he is driving the execution on all their initiatives. Richard is driving this ship not Barry.
Conix I got your private message on another ticket. Don’t pay for this service so I can’t respond. Thanks for the note. I agree w all you said. Tough days though on low volume.
I will be too. Have to put in small bids because seems like larger orders only get partially filled if that.
A reverse split is necessary to get to a higher exchange. That is the only reason they would do a RS. And yes it is coming. You are right. But not at these prices.
Totally agree Eagle. I think you are spot on. Don’t think they will RS split here. It would be stupid. The notice was to do the needed ground work for a higher exchange. Totally agree. Never a good time for that type of a notice. But gotta think they are thinking higher exchange here. And they won’t do that without news on progress and a higher stock price.
Is it just me, but doesn’t “oversee” mean that she is likely more than just a figurehead as some might think? Seems like she is pretty engaged based on her role as described by Chairman Michael’s. Time will tell the tale. We are still in the early innings here.
The question has arisen as to the prudence of Curative pursing the use of IMT504 in the development of a COVID19 vaccine. The following sheds some insight into this strategic move.
“It is becoming increasingly clear that the initial COVID-19 vaccines developed are not working for everyone. There are highly vulnerable people, such as those patients with kidney failure who require kidney transplantation or dialysis, who are being left behind. We need targeted vaccines for this immunocompromised patient group," said Curative Biotech Chairman & President Paul Michaels.
Curative Biotech and Mid-Atlantic BioTherapeutics have agreed to develop a next generation COVID-19 vaccine targeted to meet the needs of this vulnerable population. A consequence of kidney failure in general is the loss of a robust immunologic response to infections, including COVID-19. This means that kidney failure patients may get a more severe version of COVID-19 that could lead to a greater chance of hospitalization or even death.
Dr. David Horn, CEO of Mid-Atlantic BioTherapeutics, added: "It is well known that kidney transplant recipients have impaired responses to mRNA COVID-19 vaccines. Recent data from France reveals that, even after 4 vaccine shots, many kidney transplant recipients have poor responses. In addition, kidney failure patients on dialysis do not initially respond as well to current vaccines and rapidly lose measurable antibodies when compared to the general population."
This solution to the best of my knowledge could be advanced under Operation Warp Speed. Operation Warp Speed was a public–private partnership initiated by the United States government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. In short, there is a potential expedited path forward for this COVID-19 vaccine solution, which is currently not being addressed by big pharma.
What better person to have as an advisor on this and the other initiatives than Dr. Catherine Sohn?
Again, here is a link to Dr. Sohn’s bio…
https://axcellatx.com/team/catherine-a-sohn-pharm-d/
From the last press release announcing Dr. Catherine Sohn as an advisor to the Board of Director’s and the CEO:
Paul Michaels, Chairman and President of Curative Biotech stated “We are obviously extremely pleased to have Dr. Sohn on board to oversee our infectious disease programs and our macular degeneration program. Dr. Sohn will also act as the Chairman for the joint steering committees for all three clinical programs. Her impressive background and experience at the highest levels of our industry speaks for itself, and her long involvement in developing novel vaccines will prove invaluable as we develop our next generation Covid-19 vaccine to treat kidney failure patients.”
Sounds like she is pretty engaged to me. Unless of course one can provide evidence to the contrary I will take the Chairman’s input at face value on her level of engagement here. The COVID solution is an extension to IMT504’s use and treatment of rabies. So it is more of an add on to its current application. Smart move imo, particularly since Dr. Sohn started SmithKline Beecham’s vaccine program, including her work there on novel vaccines which is exactly what this would be.
One final note: Dr. Sohn, after a very successful career has her own company now. Her main purpose in life seems to be in helping other company’s and executives succeed. She shares her vast knowledge and experience with others. That is exactly what I do now in consulting in the aviation industry. I have no interest in going to work for a company. So having her as an Advisor seems more prudent than having her as an employee. It would not fit their model nor their cost structure at this time as they are still a developmental stage biotechnology company.
I’ve been adding on these dips of late. The .07’s are a good add zone imo. Low volume red days between news updates.
Attached is a reminder of the bio of their most recent advisor addition, Dr. Catherine Sohn.
https://www.globenewswire.com/news-release/2021/10/12/2312778/0/en/CURATIVE-BIOTECHNOLOGY-ANNOUNCES-DR-CATHERINE-SOHN-AS-SPECIAL-ADVISOR-TO-BOARD-AND-CEO.html
Key quote from bio:
“Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee.”
Interesting timing of the company’s announcement of developing a novel Covid-19 vaccine for kidney failure patients (in line with their rare disease strategy) with her joining as an advisor. She started SmithKline Beecham’s vaccine business. Gotta believe she can open some doors and knows the process of developing products.
CUBT Chairman Paul Michaels has NEVER been convicted of being a “wife beater”. Therefore he is innocent. Any discussion on this topic is not consistent with our laws or the Constitution and should be considered as fake news. After all, people in this country are innocent until proven guilty. Unless of course I am misinterpreting our legal system, which of course I am not.
I am glad she is fully engaged. To have Dr. Catherine Sohn as an advisor is a huge asset for the company. This will be proven out.
Quote:
“She’s not an employee. That’s a fact.”
LOL. You are correct she is not an employee. She is also on the Board of Directors of several NASDAQ companies. She is not an employee at any of those companies either. One should really understand the business model before making completely irrelevant comments.
I will be revisiting your post in short order. News is coming. Bears here feast on weak hands and fearful hearts. Patience will pay off. They will not be on the OTC very long imo. Catherine Sohn is doing far more than you will ever realize. But you have to do some work to figure that out. I’ve done the work. Please continue to push the stock down. I’m buying every dip.
Whose they? Give me one example please.
Most OTC stocks don’t have a world class team like CUBT either. This will not be on OTC too long. Have you done your due diligence on Dr. Catherine Sohn? You really should and take not of the NASDAQ boards she is on.
Quote:
“And retailers can’t do anything about it”.
What OTC stock is not majority owned by a few insiders? Insiders with a majority always have control. Are you not aware of this?
Insiders own the majority of shares. That is why there was not need to do a proxy vote.
Watch and learn grasshopper.
Glad to see the 10Q filed early.
Was thinking the same thing just yesterday. Looks just like ILUS. Was at .04 on 8/10; now at .45. Can see CUBT making the same kind of move.
Those low .07 buys looking good here. I’m long and strong CUBT!
Added more yesterday at .0711. Interesting though that only 7,400 of my 10K order was filled. Market maker games at work. I am loving this action. It is a fire sale. Best time to buy are at times like this - low volume, red days in between news cycles. CUBT long and strong. Don’t get shaken. Bears, please take note of the solid spelling and grammar here. You want to increase what little credibility you have? Use spell check.
So what does “no office more” mean exactly?
Once again Oxnous is the voice of reason. Glad you are not repeating your position on insider selling that is not happening. You can lead them to the water but can’t make them drink.
244k shares traded today. I would doubt they are by management. We have been down this path how many times now?
* correction They have not done a RS.
They have done a RS. Read my post and tell me where I said you were wrong. And yes they will need a RS to get to a big board. No question. And I think that is a good ambition.
One thing is for certain that when you start talking about share structure you have been proven wrong time and time again.
They haven’t done a reverse split. Speculate to your hearts desire.